Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.24.0.1
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Basic and diluted numerator:        
Net loss from continuing operations $ (4,488) $ (10,563) $ (9,562) $ (18,100)
Net loss from discontinued operations (3,723) (22,990) (4,395) (33,583)
Net loss $ (8,211) $ (33,553) $ (13,957) $ (51,683)
Basic and diluted denominator:        
Weighted-average common shares outstanding - basic 1,856 490 1,525 466
Weighted-average common shares outstanding - diluted 1,856 490 1,525 466
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (2.42) $ (21.54) $ (6.27) $ (38.82)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (2.42) (21.54) (6.27) (38.82)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations (2.00) (46.89) (2.88) (72.03)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations (2.00) (46.89) (2.88) (72.03)
Per share amount basic (4.42) (68.43) (9.15) (110.85)
Per share amount diluted $ (4.42) $ (68.43) $ (9.15) $ (110.85)